Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Molecular Targeting of ERKs/RSK2 Signaling in Cancers

Author(s): Yong-Yeon Cho*

Volume 23, Issue 29, 2017

Page: [4247 - 4258] Pages: 12

DOI: 10.2174/1381612823666170714142338

Price: $65

Abstract

Accumulating studies have provided concrete evidence that p90 ribosomal S6 kinase 2 (RSK2) is a key signaling molecule involved in cell proliferation, transformation, and cancer development. RSK2 is known to be an etiological gene of Coffin-Lowry Syndrome (CLS). Recently, signaling analysis and molecular biological approaches have provided concrete evidence that RSK2 plays an essential role in human cancers. Here, we will extensively discuss signaling pathways regulating RSK2 activity, the role of RSK2 in human cancer development, inhibitors suppressing RSK2 activity, and why RSK2 is an important target to develop drugs for human cancers.

Keywords: Ras signaling pathway, ERK/RSK2, cell proliferation, carcinogenesis, cancer, emerging target.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy